These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31194697)

  • 21. CD137-mediated immunotherapy for allergic asthma.
    Polte T; Foell J; Werner C; Hoymann HG; Braun A; Burdach S; Mittler RS; Hansen G
    J Clin Invest; 2006 Apr; 116(4):1025-36. PubMed ID: 16528411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TIGIT immune checkpoint blockade restores CD8
    Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
    Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
    Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
    J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.
    Westwood JA; Matthews GM; Shortt J; Faulkner D; Pegram HJ; Duong CP; Chesi M; Bergsagel PL; Sharp LL; Huhn RD; Darcy PK; Johnstone RW; Kershaw MH
    Leuk Res; 2014 Aug; 38(8):948-54. PubMed ID: 24934848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
    Glez-Vaz J; Azpilikueta A; Olivera I; Cirella A; Teijeira A; Ochoa MC; Alvarez M; Eguren-Santamaria I; Luri-Rey C; Rodriguez-Ruiz ME; Nie X; Chen L; Guedan S; Sanamed MF; Perez Gracia JL; Melero I
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of cancer with 4-1BB.
    Vinay DS; Kwon BS
    Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice.
    Ju SA; Cheon SH; Park SM; Tam NQ; Kim YM; An WG; Kim BS
    Int J Cancer; 2008 Jun; 122(12):2784-90. PubMed ID: 18360825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice.
    Forsberg MH; Ciecko AE; Bednar KJ; Itoh A; Kachapati K; Ridgway WM; Chen YG
    J Immunol; 2017 May; 198(10):3857-3868. PubMed ID: 28363905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses.
    Halstead ES; Mueller YM; Altman JD; Katsikis PD
    Nat Immunol; 2002 Jun; 3(6):536-41. PubMed ID: 12021777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
    Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
    Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
    Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
    J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
    Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
    Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death.
    Zhang B; Zhang Y; Niu L; Vella AT; Mittler RS
    J Immunol; 2010 May; 184(9):4770-8. PubMed ID: 20351189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity.
    Akhmetzyanova I; Zelinskyy G; Littwitz-Salomon E; Malyshkina A; Dietze KK; Streeck H; Brandau S; Dittmer U
    J Immunol; 2016 Jan; 196(1):484-92. PubMed ID: 26608920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.